PharmaTelevision - Novartis: Deal-making and the Increasing Attraction of Venture Funds

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Novartis: Deal-making and the Increasing Attraction of Venture Funds

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks with Tony Rosenberg, Global Head of Business Development at Novartis.

Filmed at the PharmaTelevision Studios in Oxford, England, they discuss:

• Why a biotech should choose to partner with Novartis over other pharmaceutical companies
• Targeting specific opportunities
• Tony's thoughts on the decline in the industry's deal-making
• The structure of the Novartis venture fund
• Novartis' relationship with MPM
• Exit options on transactions in the current financial climate
• 2010 through the eyes of Novartis

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Why a biotech should choose to partner with Novartis over other pharmaceutical companies

Fintan Walton:

Hello and welcome to PharmaTelevision news review here in Oxford, England. On this show I have Tony Rosenberg, who is Global Head of Business Development and Licensing at Novartis Pharma based in Basel. Morning to you, Tony Rosenberg, Novartis obviously is one of the big corps out there in the pharmaceutical space you head up the Business Development and Licensing function within Novartis , a key question obviously Novartis is out there doing deals we see doing deals and it doing all sorts of deals we will come into some of the detail of that, but how is where, what distinguishes Novartis from the rest of the pharmaceutical companies in terms of doing deals, why should a biotech company come to Novartis ?

Tony Rosenberg:

I think there is a couple of reasons that distinguish ourselves, firstly we are very research and science driven, so we look at deals in terms of are they meeting unmet medical need and do they have a mode of action that is interesting for us and it is also incredible. So we look very much at the science space right at the beginning before we start looking at sales figures, forecast et cetera. And I think biotech's appreciate that, so we work peer-to-peer with scientists of our in-house with their biotech needs. Secondly I think what is interesting is that we can offer in the end value right down the chain so in terms of right through from research through to development, through to consumer health, through to animal health for example and in fact with our Sandoz on even post patent expiry, so we are very skilled at planning out a life cycle for compound right through from the test tube through it's commercialization to the end of commercialization. And I think that's a very interesting position to be in, we have a lot of skills and capabilities that apply to those areas and in conversations with biotech that's appreciated.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Tony Rosenberg

Global Head of Business Development

Tony Rosenberg has served as a director since June 2009. Mr. Tony Rosenberg is Head of Business Development and Licensing of Novartis Pharma AG and a member of the Pharma Executive Committee. He joined Sandoz in 1980 in the UK where he held various leadership positions in sales and marketing, business development and strategic planning. In 1994 he moved to Basel, initially as international product manager (Clozaril), and undertook roles of increasing responsibility in Global Marketing, ultimately as Head Global Marketing Primary Care. In 2000 he became Global Head of the Transplant and Immunology Business Unit and began his current role in 2005. He has overseen several major in-licensing transactions in the respiratory, infectious disease, CNS areas. Tony Rosenberg has a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.

Novartis

Novartis was created in 1996 through the merger of Ciba-Geigy and Sandoz, two companies with a rich and diverse corporate history. Throughout the years, Novartis and its predecessor companies have discovered and developed many innovative products for patients and consumers worldwide.